Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases

American Journal of Transplantation

Volumn 11, Issue 12, 2011, Pages 2613-2626

  Aspord, C ^a,b,c   Laurin, D ^a,b   Richard, M J ^b,c,d   Vie, H ^e   Chaperot, L ^a,b,c   Plumas, J ^a,b,c,f  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIV GRENOBLE ALPES   (France)

^c INSERM   (France)

^d HÔPITAL MICHALLON   (France)

^e UNIVERSITÉ DE NANTES   (France)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adoptive immunotherapy; cytomegalovirus (CMV); cytotoxic T lymphocytes; lymphoproliferative disease; plasmacytoid DCs

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; HLA A ANTIGEN; TETRAMER; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ANTIVIRAL CYTOTOXIC T CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS LYMPHOPROLIFERATIVE DISEASE; HUMAN; HUMAN CELL; INFLUENZA VIRUS; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL;

ANIMALS; BETA 2-MICROGLOBULIN; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; ORGAN TRANSPLANTATION; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 82455212828     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03722.x     Document Type: Article

References (47)

1. Leen AM, Myers GD, Sili U, et al,. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166. (Pubitemid 44527351)
2. Cooper LJ., Adoptive cellular immunotherapy for childhood malignancies. Bone Marrow Transpl 2008; 41: 183-192. (Pubitemid 351188916)
3. Peggs KS,., Adoptive T,. cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther 2009; 9: 725-736.
4. Leen AM, Rooney CM, Foster AE,. Improving T cell therapy for cancer. Annu Rev Immunol 2007; 25: 243-265. (Pubitemid 46697909)
5. Walter EA, Greenberg PD, Gilbert MJ, et al,. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
6. Einsele H, Roosnek E, Rufer N, et al,. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922. (Pubitemid 35332029)
7. Peggs KS, Verfuerth S, Pizzey A, et al,. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003; 362: 1375-1377. (Pubitemid 37338339)
8. Peggs KS, Verfuerth S, Pizzey A, Chow SL, Thomson K, Mackinnon S,. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009; 49: 1851-1860.
9. Rooney CM, Smith CA, Ng CY, et al,. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
10. Rooney CM, Smith CA, Ng CY, et al,. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555. (Pubitemid 28406858)
11. Savoldo B, Goss JA, Hammer MM, et al,. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108: 2942-2949.
12. Bollard CM, Aguilar L, Straathof KC, et al,. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med 2004; 200: 1623-1633. (Pubitemid 40094186)
13. Gottschalk S, Edwards OL, Sili U, et al,. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905-1912. (Pubitemid 36237592)
14. Gerdemann U, Christin AS, Vera JF, et al,. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 2009; 17: 1616-1625.
15. Cobbold M, Khan N, Pourgheysari B, et al,. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386. (Pubitemid 41126955)
16. Zandvliet ML, Falkenburg JH, Jedema I, Willemze R, Guchelaar HJ, Meij P,. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy. J Immunother 2009; 32: 513-523.
17. Feuchtinger T, Opherk K, Bethge WA, et al,. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367.
18. Aissi-Rothe L, Decot V, Venard V, et al,. Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy. J Immunother 2010; 33: 414-424.
19. Peggs KS, Thomson K, Samuel E, et al,. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011; 52: 49-57.
20. Morgan RA, Dudley ME, Rosenberg SA,. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010; 16: 336-341.
21. Morgan RA, Dudley ME, Wunderlich JR, et al,. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129. (Pubitemid 44547756)
22. Cooper LJ, Al-Kadhimi Z, Serrano LM, et al,. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005; 105: 1622-1631. (Pubitemid 40223683)
23. Liu YJ,. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005; 23: 275-306.
24. Colonna M, Trinchieri G, Liu YJ,. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-1226. (Pubitemid 41057736)
25. Villadangos JA, Young L,. Antigen-presentation properties of plasmacytoid dendritic cells. Immunity 2008; 29: 352-361.
26. Lui G, Manches O, Angel J, Molens JP, Chaperot L, Plumas J,. Plasmacytoid dendritic cells capture and cross-present viral antigens from influenza-virus exposed cells. PLoS One 2009; 4: e7111.
27. Fonteneau JF, Gilliet M, Larsson M, et al,. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood 2003; 101: 3520-3526. (Pubitemid 36857937)
28. Le Bon A, Etchart N, Rossmann C, et al,. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-1015. (Pubitemid 37265922)
29. Cella M, Facchetti F, Lanzavecchia A, Colonna M,. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1: 305-310.
30. Rothenfusser S, Hornung V, Ayyoub M, et al,. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 2004; 103: 2162-2169. (Pubitemid 38326234)
31. Yoneyama H, Matsuno K, Toda E, et al,. Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 2005; 202: 425-435. (Pubitemid 41126960)
32. Chaperot L, Blum A, Manches O, et al,. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006; 176: 248-255. (Pubitemid 43023269)
33. Aspord C, Charles J, Leccia MT, et al,. A novel cancer vaccine strategy based on HLA-A*0201 matched allogeneic plasmacytoid dendritic cells. PLoS One 2010; 5: e10458.
34. Retiere C, Prod'homme V, Imbert-Marcille BM, Bonneville M, Vie H, Hallet MM,. Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: A tool to study the fine specificity of the antiviral response. J Virol 2000; 74: 3948-3952. (Pubitemid 30214399)
35. Leen AM, Tripic T, Rooney CM,. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2007; 10: 337-351.
36. Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ,. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: An approach for adoptive immunotherapy of multiple pathogens. J Immunother 2007; 30: 544-556. (Pubitemid 46988088)
37. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME,. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299-308. (Pubitemid 351430867)
38. Hinrichs CS, Gattinoni L, Restifo NP,. Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol 2006; 18: 363-740.
39. Gattinoni L, Klebanoff CA, Palmer DC, et al,. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115: 1616-1626. (Pubitemid 40814670)
40. Romero P, Zippelius A, Kurth I, et al,. Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 2007; 178: 4112-4119. (Pubitemid 46492360)
41. van Lier RA, ten Berge IJ, Gamadia LE,. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol 2003; 3: 931-939.
42. Aspord C, Yu CI, Banchereau J, Palucka AK,. Humanized mice for development and testing of human vaccines. Expert Opin Drug Discov 2007; 2: 949-960. (Pubitemid 47162381)
43. Lin CL, Lo WF, Lee TH, et al,. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952-6958.
44. Di Pucchio T, Chatterjee B, Smed-Sorensen A, et al,. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008; 9: 551-557. (Pubitemid 351560524)
45. Young LJ, Wilson NS, Schnorrer P, et al,. Differential MHC class II synthesis and ubiquitination confers distinct antigen-presenting properties on conventional and plasmacytoid dendritic cells. Nat Immunol 2008; 9: 1244-1252.
46. van den Hoorn T, Neefjes J,. Activated pDCs: open to new antigen-presentation possibilities. Nat Immunol 2008; 9: 1208-1210.
47. Abe M, Wang Z, de Creus A, Thomson AW,. Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transpl 2005; 5: 1808-1819. (Pubitemid 41039853)